文献速递间质性肺疾病

端粒长度检测对间质性肺疾病的临床影响

Clinical Impact of Telomere Length Testing for Interstitial Lung Disease.
PubMed 文献 · Chest · 2024-06-29

该研究在哥伦比亚大学ILD门诊对108例患者进行FlowFISH端粒长度检测,发现46%存在短端粒,且短端粒临床特征数量与检出短端粒独立相关(OR 2.00)。端粒检测使32%患者治疗改变,主要为减少或避免免疫抑制,并帮助重新分类部分意义不明变异。

要点

  • 46%的ILD患者检出短端粒,与具体ILD诊断无关。
  • 短端粒临床特征数量与检出短端粒独立相关(OR 2.00)。
  • 端粒检测使32%患者治疗改变,多为减少或避免免疫抑制。

核心结论

  • 在ILD管理中纳入端粒长度检测影响了临床决策,并发现了新的可操作遗传变异。

研究设计与样本

  • 在哥伦比亚大学ILD门诊评估患者,行CLIA认证的FlowFISH端粒长度检测作为临床诊疗的一部分。
  • 共108例患者接受端粒长度检测,短端粒定义为FlowFISH粒细胞或淋巴细胞年龄校正第10百分位以下。
  • 有短端粒或ILD家族史的患者接受遗传咨询和检测,FlowFISH结果与研究用qPCR端粒长度测量进行比较。

主要发现

  • 短端粒总体患病率为46%,在不同临床ILD诊断间相似。
  • 短端粒临床特征数量与检出短端粒独立相关(OR 2.00;95% CI 1.27-3.32)。
  • 端粒检测导致35例(32%)患者临床治疗改变,最常见为减少或避免免疫抑制。
  • 34例接受基因检测的患者中,10例(29%)发现端粒相关基因的阳性或候选诊断性变异。
  • 纳入第1百分位以下的端粒长度检测帮助将9个意义不明变异中的8个重新分类为可操作发现。

关键数值与推荐

  • 短端粒定义为FlowFISH粒细胞或淋巴细胞年龄校正第10百分位以下。
  • 短端粒临床特征数量与检出短端粒的OR为2.00(95% CI 1.27-3.32)。
  • qPCR与FlowFISH相关,但两种检测的年龄校正百分位截断值可能不等效。

临床怎么用

  • 对具有短端粒临床特征(如家族性肺纤维化、肺外表现或亲属相关表现)的ILD患者可考虑端粒长度检测。
  • 端粒检测结果可指导免疫抑制治疗的决策,如减少或避免使用。
  • 端粒检测可辅助遗传咨询和基因检测,帮助重新分类意义不明变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shortened telomere length (TL) is a genomic risk factor for fibrotic interstitial lung disease (ILD), but its role in clinical management is unknown. RESEARCH QUESTION: What is the clinical impact of TL testing on the management of ILD? STUDY DESIGN AND METHODS: Patients were evaluated in the Columbia University ILD clinic and underwent Clinical Laboratory Improvement Amendments-certified TL testing by flow cytometry and fluorescence in situ hybridization (FlowFISH) as part of clinical treatment. Short TL was defined as below the 10th age-adjusted percentile for either granulocytes or lymphocytes by FlowFISH. Patients were offered genetic counseling and testing if they had short TL or a family history of ILD. FlowFISH TL was compared with research quantitative polymerase chain reaction (qPCR) TL measurement. RESULTS: A total of 108 patients underwent TL testing, including those with clinical features of short telomere syndrome such as familial pulmonary fibrosis (50%) or extrapulmonary manifestations in the patient (25%) or a relative (41%). The overall prevalence of short TL was 46% and was similar across clinical ILD diagnoses. The number of short telomere clinical features was independently associated with detecting short TL (OR, 2.00; 95% CI, 1.27-3.32). TL testing led to clinical treatment changes for 35 patients (32%), most commonly resulting in reduction or avoidance of immunosuppression. Of the patients who underwent genetic testing (n = 34), a positive or candidate diagnostic finding in telomere-related genes was identified in 10 patients (29%). Inclusion of TL testing below the 1st percentile helped reclassify eight of nine variants of uncertain significance into actionable findings. The quantitative polymerase chain reaction test correlated with FlowFISH, but age-adjusted percentile cutoffs may not be equivalent between the two assays. INTERPRETATION: Incorporating TL testing in ILD impacted clinical management and led to the discovery of new actionable genetic variants.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhang D, Eckhardt CM, McGroder C, et al. Clinical Impact of Telomere Length Testing for Interstitial Lung Disease. Chest. 2024. PMID: 38950694. doi:10.1016/j.chest.2024.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。